



Timely Administration of the Hepatitis B Birth Dose Vaccine

Guest Editors:

Dr. Yusuke Shimakawa

Unité d'Epidémiologie des
Maladies Emergentes, Institut
Pasteur, 75015 Paris, France

Dr. Youkyung Choi

Division of Viral Hepatitis,
National Center for HIV/AIDS,
Viral Hepatitis, STD and TB
Prevention, The Centers for
Disease Control and Prevention,
Atlanta, GA 30329, USA

Deadline for manuscript
submissions:

closed (31 March 2021)

Message from the Guest Editors

Dear Colleagues,

To achieve the WHO's objective to globally eliminate hepatitis B virus (HBV) infection by 2030, it is essential to prevent mother-to-child transmission of HBV. Administration of the hepatitis B vaccine to neonates, preferably within 24 hours after birth, is a key intervention recommended by the WHO to reach this goal. However, the timely administration of the hepatitis B birth dose vaccine (HepB-BD) has not been well implemented in low- and middle-income countries for multiple reasons, including a high rate of childbirth at home.

This Special Issue aims to uncover the current situation of the implementation of the HepB-BD, the challenges and facilitators for its timely administration, and potential innovations to overcome these problems. This Special Issue welcomes the submission of papers from a wide range of disciplines including basic science, clinical/epidemiological research, social/anthropological studies, and health economy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com